[go: up one dir, main page]

CL2016001098A1 - Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales - Google Patents

Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales

Info

Publication number
CL2016001098A1
CL2016001098A1 CL2016001098A CL2016001098A CL2016001098A1 CL 2016001098 A1 CL2016001098 A1 CL 2016001098A1 CL 2016001098 A CL2016001098 A CL 2016001098A CL 2016001098 A CL2016001098 A CL 2016001098A CL 2016001098 A1 CL2016001098 A1 CL 2016001098A1
Authority
CL
Chile
Prior art keywords
derivatives
treatment
cysteamine
mitochondrial diseases
mitochondrial
Prior art date
Application number
CL2016001098A
Other languages
English (en)
Inventor
Patrice Rioux
Todd C Zankel
Original Assignee
Raptor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raptor Pharmaceuticals Inc filed Critical Raptor Pharmaceuticals Inc
Publication of CL2016001098A1 publication Critical patent/CL2016001098A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METODO DE TRATAMIENTO DE UN TRASTORNO MITOCONDRIAL HEREDADO O ADQUIRIDO QUE COMPRENDE ADMINISRAR CISTEAMINA O CISTAMINA O SUS DERIVADOS.
CL2016001098A 2013-11-06 2016-05-06 Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales CL2016001098A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361900772P 2013-11-06 2013-11-06

Publications (1)

Publication Number Publication Date
CL2016001098A1 true CL2016001098A1 (es) 2016-12-23

Family

ID=53007221

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001098A CL2016001098A1 (es) 2013-11-06 2016-05-06 Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales

Country Status (13)

Country Link
US (1) US20150125526A1 (es)
EP (1) EP3065725A4 (es)
JP (1) JP2016540827A (es)
KR (1) KR20160070154A (es)
CN (1) CN105873579A (es)
CA (1) CA2928442A1 (es)
CL (1) CL2016001098A1 (es)
EA (1) EA201690936A1 (es)
IL (1) IL245231A0 (es)
MX (1) MX2016005858A (es)
PH (1) PH12016500842A1 (es)
TW (1) TW201605434A (es)
WO (1) WO2015069888A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016288230A1 (en) 2015-07-02 2018-01-25 Horizon Orphan Llc ADO-resistant cysteamine analogs and uses thereof
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2018013811A1 (en) * 2016-07-14 2018-01-18 The Regents Of The University Of California Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
US11662339B1 (en) * 2016-11-02 2023-05-30 Kyoto University Efficacy determination markers in disease treatment by PD-1 signal inhibitor
GB2581362A (en) 2019-02-14 2020-08-19 Univ Of Sunderland Chemical synthesis
KR102290596B1 (ko) * 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도
WO2022249942A1 (ja) * 2021-05-24 2022-12-01 国立大学法人岩手大学 網膜の神経細胞の保護剤
CN119909064B (zh) * 2025-04-07 2025-08-15 北京大学深圳研究生院 胱胺衍生物或其盐以及其在制备具有抗氧化功效的药物中的应用
CN120437102B (zh) * 2025-07-09 2025-09-16 中南大学湘雅医院 胱胺在制备治疗脓毒症脑病药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001270303A1 (en) * 2000-07-07 2002-01-21 Incyte Genomics, Inc. Drug metabolizing enzymes
US20110301235A1 (en) * 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
US20120309785A1 (en) * 2010-12-03 2012-12-06 Bill Piu Chan Use of Cysteamine in Treating Parkinson's Disease

Also Published As

Publication number Publication date
EP3065725A4 (en) 2017-06-14
CN105873579A (zh) 2016-08-17
MX2016005858A (es) 2016-08-11
WO2015069888A2 (en) 2015-05-14
IL245231A0 (en) 2016-06-30
KR20160070154A (ko) 2016-06-17
TW201605434A (zh) 2016-02-16
EA201690936A1 (ru) 2016-08-31
PH12016500842A1 (en) 2016-07-04
EP3065725A2 (en) 2016-09-14
JP2016540827A (ja) 2016-12-28
CA2928442A1 (en) 2015-05-14
WO2015069888A3 (en) 2015-11-12
US20150125526A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CL2016001098A1 (es) Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales
CL2016000392A1 (es) Análogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
LT3206715T (lt) Kanabidiolio naudojimas tuberozinės sklerozės komplekso gydymui
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
NI201600071A (es) Compuestos de inhibidor de autotaxina
PL3145522T3 (pl) Kombinacja, kompozycja i sposób podawania kombinacji lub kompozycji zwierzętom
CL2017001046A1 (es) Inhibidoes del bromodominio
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
IL259025A (en) Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
PT3218005T (pt) Compostos que interagem com glicano e métodos de uso
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
PL3426302T3 (pl) Leczenie chorób autoimmunologicznych przy użyciu skojarzenia agonistów rxr z hormonami tarczycy
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
PT3511004T (pt) Preparações combinadas para o tratamento de cancro
DK3463436T3 (da) Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling
CL2016002779A1 (es) Composición para el cuidado de la piel
CL2015001936A1 (es) Composición y su uso que sirve para preparar un medicamento útil para tratar enfermedades relacionadas con el factor inducible por hipoxia (hif).